论文信息 - Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

We have designed and synthesized a novel series of 2,8-diaryl-quinoxalines as Janus kinase 2 inhibitors. Many of the inhibitors show low nanomolar activity against JAK2 and potently suppress proliferation of SET-2 cells in vitro. In addition, compounds from this series have favorable rat pharmacokinetic properties suitable for in vivo efficacy evaluation.

[1] D. Gilliland,et al. JAK2 in Myeloproliferative Disorders Is Not Just Another Kinase , 2005, Cell cycle.

[2] J. Comer,et al. Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class. , 2008, Current drug metabolism.

[3] T. Boggon,et al. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.

[4] S. Rane,et al. Janus kinases: components of multiple signaling pathways , 2000, Oncogene.

[5] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[6] P. Ertl,et al. Computational approaches to determine drug solubility. , 2007, Advanced drug delivery reviews.

[7] P. Furet,et al. Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing. , 2010, Bioorganic & medicinal chemistry letters.

[8] Eric Vangrevelinghe,et al. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[9] D. Gary Gilliland,et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders , 2007, Nature Reviews Cancer.